NASDAQ
ANGN

Angion Biomedica Corp

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Angion Biomedica Corp Stock Price

Vitals

Today's Low:
$8.901
Today's High:
$10.6
Open Price:
$10.6
52W Low:
$0.59
52W High:
$2.625
Prev. Close:
$9.8
Volume:
224845

Company Statistics

Market Cap.:
$19.53 million
Book Value:
1.667
Revenue TTM:
$28.24 million
Operating Margin TTM:
-42.13%
Gross Profit TTM:
$-20819000
Profit Margin:
-61.88%
Return on Assets TTM:
-8.68%
Return on Equity TTM:
-30.47%

Company Profile

Angion Biomedica Corp had its IPO on 2021-02-05 under the ticker symbol ANGN.

The company operates in the Healthcare sector and Biotechnology industry. Angion Biomedica Corp has a staff strength of 71 employees.

Stock update

Shares of Angion Biomedica Corp opened at $10.6 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $8.9 - $10.6, and closed at $10.

This is a +2.04% increase from the previous day's closing price.

A total volume of 224,845 shares were traded at the close of the day’s session.

In the last one week, shares of Angion Biomedica Corp have increased by +19.23%.

Angion Biomedica Corp's Key Ratios

Angion Biomedica Corp has a market cap of $19.53 million, indicating a price to book ratio of 0.4859 and a price to sales ratio of 0.8958.

In the last 12-months Angion Biomedica Corp’s revenue was $28.24 million with a gross profit of $-20819000 and an EBITDA of $-11718000. The EBITDA ratio measures Angion Biomedica Corp's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Angion Biomedica Corp’s operating margin was -42.13% while its return on assets stood at -8.68% with a return of equity of -30.47%.

In Q3, Angion Biomedica Corp’s quarterly earnings growth was a positive 0% while revenue growth was a positive 20.9%.

Angion Biomedica Corp’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-0.49 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Angion Biomedica Corp’s profitability.

Angion Biomedica Corp stock is trading at a EV to sales ratio of 2.2573 and a EV to EBITDA ratio of 2.4526. Its price to sales ratio in the trailing 12-months stood at 0.8958.

Angion Biomedica Corp stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$61.32 million
Total Liabilities
$8.18 million
Operating Cash Flow
$0
Capital Expenditure
$0
Dividend Payout Ratio
0%

Angion Biomedica Corp ended 2024 with $61.32 million in total assets and $0 in total liabilities. Its intangible assets were valued at $61.32 million while shareholder equity stood at $50.21 million.

Angion Biomedica Corp ended 2024 with $0 in deferred long-term liabilities, $8.18 million in other current liabilities, 301000.00 in common stock, $-247502000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $55.14 million and cash and short-term investments were $55.14 million. The company’s total short-term debt was $1,032,000 while long-term debt stood at $0.

Angion Biomedica Corp’s total current assets stands at $56.68 million while long-term investments were $874000.00 and short-term investments were $0. Its net receivables were $7000.00 compared to accounts payable of $2.22 million and inventory worth $0.

In 2024, Angion Biomedica Corp's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Angion Biomedica Corp paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$10
52-Week High
$2.625
52-Week Low
$0.59
Analyst Target Price
$1.5

Angion Biomedica Corp stock is currently trading at $10 per share. It touched a 52-week high of $2.625 and a 52-week low of $2.625. Analysts tracking the stock have a 12-month average target price of $1.5.

Its 50-day moving average was $7.08 and 200-day moving average was $8.18 The short ratio stood at 0.68 indicating a short percent outstanding of 0%.

Around 3301.5% of the company’s stock are held by insiders while 1635.5% are held by institutions.

Frequently Asked Questions About Angion Biomedica Corp

The stock symbol (also called stock or share ticker) of Angion Biomedica Corp is ANGN

The IPO of Angion Biomedica Corp took place on 2021-02-05

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$157
0
0%
$76.8
-0.24
-0.31%
BNR UDYOG LTD. (BNRUDY)
$41.03
-1.91
-4.45%
$51.25
2.4
+4.91%
$708.45
-31.2
-4.22%
TCM LTD. (TCMLMTD)
$39.33
-2.28
-5.48%
$14.87
-0.12
-0.8%
$234.05
-16.8
-6.7%
$22.46
-0.09
-0.4%
$424.08
-0.92
-0.22%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company’s lead product candidate is ANG-3070, an oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, primarily in the kidney and lung. It also develops ANG-3777, a hepatocyte growth factor mimetic to treat acute organ injuries, such as delayed graft function; ROCK2 inhibitors programs for fibrotic diseases; and CYP11B2 inhibitor program. The company was incorporated in 1998 and is based in Uniondale, New York.

Address

51 Charles Lindbergh Boulevard, Uniondale, NY, United States, 11553